signific
concern
rais
owe
rapid
global
spread
infect
diseas
caus
mosquitoborn
zika
viru
zikv
recent
studi
suggest
zikv
also
transmit
sexual
increas
exposur
risk
viru
associ
spread
dramat
increas
case
microcephali
addit
congenit
abnorm
infant
zikvinfect
mother
well
rise
occurr
guillain
barr
syndrom
infect
adult
importantli
licens
therapi
vaccin
zikv
infect
studi
gener
evalu
vivo
efficaci
novel
synthet
dna
vaccin
target
premembraneenvelop
protein
prme
zikv
follow
initi
vitro
develop
evalu
studi
plasmid
construct
mice
nonhuman
primat
immunis
prme
dnabas
immunogen
electroporationmedi
enhanc
dna
deliveri
vaccin
anim
found
gener
antigenspecif
cellular
humor
immun
neutralis
activ
mice
lack
receptor
interferon
ifn
design
ifnar
immunis
dna
vaccin
induc
follow
vivo
viral
challeng
protect
infectionassoci
weight
loss
death
addit
prevent
viral
patholog
brain
tissu
addit
passiv
transfer
nonhuman
primat
antizikv
immun
serum
protect
ifnar
mice
subsequ
viral
challeng
studi
nhp
pathogen
mous
model
support
import
immun
respons
target
prme
zikv
infect
suggest
addit
research
vaccin
approach
may
relev
zikv
control
diseas
prevent
human
zika
viru
zikv
singlestrand
posit
sens
rna
flaviviru
spread
primarili
bite
infect
aed
mosquito
howev
recent
outbreak
south
central
america
novel
mechan
zikv
transmiss
describ
includ
sexual
transplacent
transmiss
viru
endem
part
africa
asia
spread
unab
south
america
mexico
caribbean
last
year
factor
includ
increas
global
travel
expans
rang
aed
mosquito
owe
climat
chang
portend
spread
viru
expand
rang
southern
unit
state
next
year
zikv
infect
present
prodrom
myalgia
arthralgia
malais
lowgrad
fever
rash
appear
approxim
day
post
infect
may
occur
conjunct
retroorbit
pain
clinic
present
similar
albeit
less
sever
chikungunya
dengu
viral
infect
also
transmit
mosquito
vector
french
polynesian
outbreak
increas
risk
guillain
barr
syndrom
identifi
infect
individu
alarmingli
recent
outbreak
south
central
america
microcephali
congenit
abnorm
infant
observ
mother
infect
zikv
pregnanc
april
unit
state
center
diseas
control
prevent
confirm
link
zikv
infect
microcephali
establish
zikv
teratogen
current
licens
therapi
vaccin
zikv
infect
therefor
develop
evalu
potenti
vaccin
control
halt
spread
rapidli
emerg
infecti
agent
high
prioriti
describ
develop
evalu
synthet
zikv
prme
dna
vaccin
deliv
electropor
immunogen
impact
zikv
infect
pathogen
anim
challeng
model
construct
zikvprm
consensu
dna
vaccin
consensu
sequenc
zikv
prm
precursor
membran
envelop
env
gene
zikvprm
gener
use
prm
env
sequenc
variou
zikv
isol
year
caus
infect
human
zikvprm
consensu
sequenc
clone
vector
addit
modif
optimis
made
improv
vivo
express
includ
addit
highli
effici
immunoglobulin
e
ige
leader
peptid
sequenc
figur
optim
align
zikvenv
sequenc
perform
use
homolog
model
visualis
discoveri
studio
refer
model
includ
pdb
pdb
align
residu
correspond
specif
region
prme
antigen
label
model
visualis
purpos
figur
optimis
consensu
vaccin
select
gener
conserv
semiconserv
rel
multipl
zikv
strain
analys
studi
structur
studi
edespecif
neutralis
antibodi
reveal
recognit
determin
found
serotypeinvari
site
envdim
interfac
includ
expos
main
chain
fusion
loop
two
conserv
glycan
chain
glycan
two
glycosyl
site
highli
conserv
flavivirus
moreov
zikv
possess
glycosyl
site
glycosyl
site
equival
glycosyl
site
dengu
absent
isol
zikv
strain
part
consensu
design
therefor
design
construct
leav
glycosyl
site
lack
glycosyl
site
correl
improv
bind
type
broadli
neutralis
antibodi
bnab
zikvenv
protein
subsequ
construct
express
zikvprm
protein
plasmid
confirm
western
blot
analysi
indirect
immunofluoresc
assay
ifa
protein
extract
prepar
cell
transient
transfect
zikvprm
analys
express
western
blot
use
panflaviviru
antibodi
figur
sera
collect
zikvprm
immunis
mice
figur
zikvprm
express
detect
ifa
stain
cell
transfect
figur
construct
zikvprm
consensu
dna
vaccin
diagrammat
represent
zikvprm
dna
vaccin
indic
clone
prme
mammalian
express
vector
consensu
design
strategi
adopt
zikvprm
consensu
sequenc
codonoptimis
synthet
gene
prme
construct
includ
synthet
ige
leader
sequenc
optimis
gene
construct
insert
site
modifi
vector
control
cmv
promot
b
model
build
zikv
protein
demonstr
overlap
vaccin
target
potenti
relev
epitop
region
sever
chang
made
vaccin
design
purpos
locat
domain
ii
iii
locat
within
dash
line
inset
middl
left
vaccinespecif
residu
chang
region
shown
violet
cpk
format
ribbon
backbon
represent
e
env
protein
dimer
chain
light
dark
green
respect
region
correspond
defin
ede
indic
cyan
fusion
loop
indic
blue
residu
vaccin
e
protein
model
expos
surfac
loop
part
nlink
glycosyl
motif
nxst
sever
zikv
strain
well
multipl
dengu
viru
strain
c
express
analysi
sdspage
zikvprm
protein
express
cell
use
western
blot
analysi
cell
transfect
zikvprm
plasmid
cell
lysat
supernat
analys
express
vaccin
construct
panflaviviru
c
sera
zikvprm
immun
mice
protein
molecular
weight
marker
kda
cell
lysat
supernat
zikvprm
transfect
cell
rzikv
posit
control
load
indic
e
immunofluoresc
assay
ifa
analysi
zikvprm
protein
express
cell
cell
transfect
zikvprm
plasmid
twentyfour
hour
post
transfect
immunofluoresc
label
perform
addit
sera
zikvprm
immunis
mice
follow
addit
secondari
antimous
antibodi
detect
stain
sera
zikvprm
immunis
mice
shown
dapi
panel
show
control
stain
cell
nuclei
overlay
panel
combin
antimous
dapi
stain
pattern
dapi
zikvprm
precursor
membran
env
zika
viru
zikvprm
plasmid
h
post
transfect
antizikvprm
specif
antibodi
figur
zikvprm
dna
vaccin
induc
antigenspecif
cell
mice
abil
zikvprm
plasmid
vaccin
induc
cellular
immun
respons
evalu
group
four
femal
mice
immunis
either
control
plasmid
backbon
zikvprm
plasmid
vaccin
three
time
week
interv
intramuscular
im
inject
follow
electropor
site
deliveri
figur
one
week
third
inject
bulk
splenocyt
harvest
anim
evalu
elispot
assay
abil
secret
ex
vivo
exposur
peptid
pool
encompass
zikvprm
assay
result
show
splenocyt
zikvprm
immunis
mice
produc
cellular
immun
respons
stimul
multipl
zikv
peptid
pool
figur
region
zikvenv
elicit
strongest
cellular
respons
evalu
elispot
assay
matrix
format
use
peptid
pool
consist
overlap
amino
acid
span
entir
zikvprm
protein
sever
pool
demonstr
elev
cell
respons
peptid
pool
exhibit
highest
number
spotform
unit
sfu
figur
matrix
map
analysi
reveal
domin
prme
epitop
ircigvsnr
dfvegm
peptid
confirm
contain
restrict
epitop
analysi
utilis
immun
epitop
databas
analysi
resourc
tool
http
toolsiedborg
haplotyp
antigen
effect
process
evalu
cellular
immunogen
zikvprm
vaccin
entail
determin
polyfunct
properti
cell
collect
week
final
immunis
result
show
zikvprm
vaccin
increas
proport
bifunct
vaccinespecif
cell
express
tumour
necrosi
importantli
zikvprm
vaccin
exhibit
strong
abil
expand
cell
function
figur
addit
compar
immun
studi
perform
optimis
plasmid
encod
prme
sequenc
either
recent
identifi
brazilian
zikv
strain
origin
zikv
strain
induct
cellular
immun
respons
mice
immunis
either
plasmid
measur
week
third
vaccin
elispot
analysi
stimul
splenocyt
zikvprm
peptid
pool
result
illustr
tcell
respons
induc
consensu
zikvprm
dna
vaccin
construct
consist
higher
gener
either
two
nonconsensu
figur
characteris
cellular
immun
respons
mice
follow
vaccin
zikvprm
dna
vaccin
timelin
vaccin
immunis
immun
analysi
use
studi
b
elispot
analysi
measur
secret
splenocyt
respons
zikvprm
immunis
mice
n
immunis
im
three
time
either
zikvprm
dna
vaccin
follow
electropor
gener
indic
induct
cellular
immun
respons
measur
elispot
assay
splenocyt
harvest
week
third
immunis
incub
presenc
one
six
peptid
pool
span
entir
prm
env
protein
result
shown
stack
bar
graph
data
repres
averag
number
sfu
spotform
unit
per
million
splenocyt
valu
repres
mean
respons
sem
c
epitop
composit
zikvprmespecif
respons
determin
stimul
matrix
peptid
pool
week
third
immunis
valu
repres
mean
respons
group
sem
experi
perform
independ
least
three
time
similar
result
flow
cytometr
analysi
tcell
respons
immunis
zikvprm
induc
higher
number
secret
cell
stimul
zikv
peptid
one
week
last
immunis
zikvprm
vaccin
splenocyt
cultur
presenc
pool
zikv
peptid
frequenc
zikv
peptidespecif
secret
cell
measur
flow
cytometri
singl
function
gate
set
base
neg
control
unstimul
sampl
place
consist
across
sampl
percentag
total
tcell
respons
shown
data
repres
two
independ
immunis
experi
ifn
interferon
tnf
tumour
necrosi
factor
zikvprm
precursor
membran
env
zika
viru
plasmid
vaccin
supplementari
figur
b
detail
map
analysi
cellular
respons
induc
either
brazilian
prme
vaccin
reveal
vaccin
induc
signific
cellular
respons
domin
envspecif
ctl
epitop
identifi
figur
c
consensu
zikvprm
plasmid
data
shown
consensu
immunogen
consist
induc
robust
respons
tcell
assay
dose
evalu
addit
assay
gener
zikv
recombin
envelop
protein
onset
studi
avail
commerci
reagent
evalu
specif
antizikv
immun
respons
therefor
necess
recombin
zikvenv
protein
rzikv
gener
support
assay
perform
studi
gener
reagent
consensu
zikvenv
sequenc
base
zikvprm
vaccin
consensu
antigen
clone
escherichia
coli
express
vector
supplementari
figur
rzikv
antigen
produc
e
coli
cultur
purifi
use
nickel
column
chromatographi
analys
use
sdspage
show
overexpress
protein
predict
size
lysat
rzikv
transfect
bacteria
could
detect
western
analysi
use
antihi
tag
antibodi
supplementari
figur
sera
mice
immunis
zikvprm
vaccin
bound
rzikvenv
use
captur
antigen
elisa
enzymelink
immunosorb
assay
supplementari
figur
commerci
antibodi
design
panflaviviru
react
env
protein
multipl
flavivirus
also
bound
rzikv
western
analysi
demonstr
immun
sera
zikvprm
immunis
mice
specif
recognis
rzikv
supplementari
figur
data
indic
gener
rzikv
react
specif
immun
sera
zikvprm
vaccin
mice
thu
recombin
protein
use
immunogen
studi
induct
function
humor
respons
mice
zikvprm
dna
vaccin
abil
consensu
zikvprm
vaccin
induc
humor
immun
respons
mice
evalu
group
four
mice
immunis
intramuscularli
im
electroporationmedi
deliveri
three
time
interv
either
empti
control
consensu
zikvprm
vaccin
plasmid
sera
obtain
immun
mous
test
elisa
zikvspecif
igg
respons
use
immobilis
rzikv
captur
antigen
signific
increas
antizikvspecif
igg
observ
day
boost
sera
igg
level
note
day
figur
day
sera
vaccin
anim
show
figur
antizikv
antibodi
respons
induc
zikvprm
vaccin
elisa
analysi
measur
bind
antibodi
product
measur
valu
immunis
mice
mice
n
immunis
im
three
time
zikvprm
plasmid
interv
bind
rzikv
analys
sera
anim
differ
time
point
day
post
immunis
variou
dilut
data
shown
repres
least
three
separ
experi
b
endpoint
bind
titr
analysi
differ
antizikv
endpoint
titr
produc
respons
zikvprm
immunogen
analys
sera
immunis
anim
boost
c
western
blot
analysi
rzikv
specif
antibodi
induc
zikvprm
immunis
rzikv
protein
electrophores
sd
polyacrylamid
gel
analys
western
blot
analysi
pool
sera
zikvprm
immunis
mice
day
bind
rzikv
indic
arrowhead
immunofluoresc
analysi
zikv
specif
antibodi
induc
zikvprm
immunis
vero
cell
infect
either
mock
infect
stain
pool
sera
zikvprm
immunis
mice
day
follow
secondari
antibodi
detect
e
plaquereduct
neutralis
prnt
assay
analysi
neutralis
antibodi
induc
zikvprm
immunis
serum
sampl
zikvprm
immunis
mice
test
abil
neutralis
zikv
infect
vitro
prnt
defin
serum
dilut
factor
could
inhibit
input
viru
valu
parenthes
indic
prnt
control
zikvcap
dna
vaccin
express
zikv
capsid
protein
sera
use
neg
control
zikvprm
precursor
membran
env
zika
viru
elev
zikvspecif
antibodi
respons
maintain
long
term
follow
final
boost
importantli
sera
vaccin
mice
contain
high
level
rzikvespecif
antibodi
indic
endpoint
titr
figur
addit
assess
specif
vaccineinduc
antibodi
perform
screen
pool
sera
zikvprm
plasmid
inocul
mice
abil
detect
rzikv
western
analysi
figur
stain
zikv
strain
infect
cell
immunofluoresc
assay
figur
result
analys
confirm
specif
vaccineinduc
humor
respons
furthermor
zikvspecif
bind
antibodi
respons
also
assess
mice
immunis
plasmid
encod
prme
sequenc
brazilian
strain
strain
describ
day
week
third
immunis
sera
nonconsensu
vaccineimmunis
mice
analys
elisa
bind
rzikv
analysi
indic
brazil
vaccin
plasmid
induc
signific
antibodi
bind
immunis
consensu
zikvprm
dna
vaccin
gener
effect
humor
respons
rzikv
supplementari
figur
plaqu
reduct
neutralisz
test
prnt
assay
perform
pool
day
sera
mice
immunis
either
control
plasmid
consensu
zikvprm
plasmid
vaccin
consensu
zikvc
capsid
plasmid
vaccin
prnt
assay
use
method
adapt
previous
describ
techniqu
analys
dengu
viru
west
nile
viru
flavivirus
shown
figur
zikvprm
vaccin
yield
signific
neutralis
respons
antizikv
reciproc
prnt
dilut
titr
invers
serum
dilut
control
zikv
infect
inhibit
wherea
sera
zikvcap
dna
vaccin
immun
mice
minim
higher
sera
control
plasmid
vaccin
anim
titr
immun
respons
protect
zikv
mice
lack
type
interferon
receptor
ifnar
follow
immunis
zikvprm
dna
vaccin
mechan
zikvinduc
diseas
immun
poorli
defin
protect
versu
hypothet
pathogen
natur
immun
respons
zikv
infect
yet
unclear
strain
mice
resist
zikv
infect
howev
mice
lack
receptor
ifnar
found
suscept
infect
diseas
succumb
within
day
post
challeng
abil
consensu
zikvprm
plasmid
vaccin
induc
cellular
humor
immun
respons
mous
strain
investig
five
six
week
old
femal
ifnar
mice
n
immunis
im
electroporationmedi
deliveri
three
time
interv
either
control
plasmid
zikvprm
vaccin
plasmid
vaccin
serum
collect
immunis
mice
day
splenocyt
harvest
mice
week
follow
final
immunis
day
splenocyt
vaccineimmunis
mice
produc
clear
cellular
immun
respons
indic
level
sfu
per
cell
elispot
assay
supplementari
figur
result
elisa
analysi
use
rzikv
captur
antigen
show
detect
antizikv
serum
igg
day
titr
level
boost
subsequ
vaccin
bind
antibodi
titr
reach
least
supplementari
figur
c
comparison
prnt
titr
day
postimmunis
sampl
data
shown
result
indic
ifnar
mice
immunis
consensu
zikvprm
vaccin
capabl
gener
antizikv
cellular
humor
immun
respons
support
studi
model
put
vaccin
effect
pathogen
challeng
zikvspecif
function
cellular
humor
respons
elicit
zikvprm
dna
vaccin
nonhuman
primat
nhp
immunis
intraderm
immunis
use
intraderm
electropor
base
recent
studi
show
potent
immun
respons
intraderm
format
rhesu
macaqu
rm
n
administ
mg
vaccin
plasmid
intraderm
electropor
anim
vaccin
twice
week
apart
sera
peripher
blood
mononuclear
cell
pbmc
collect
day
preimmunis
week
week
post
second
immunis
elispot
analysi
preimmunis
week
pbmc
ex
vivo
stimul
zikvprm
peptid
pool
show
zikvprm
immunis
induc
robust
antizikv
cell
respons
rm
figur
specif
antizikv
antibodi
respons
sera
vaccin
rm
assess
elisa
week
rzikvespecif
bind
antibodi
detect
anim
vaccin
zikvprm
figur
endpoint
titr
determin
anim
week
immunis
week
immunis
figur
elisa
result
confirm
western
blot
analysi
use
rm
sera
individu
vaccin
anim
figur
neutralis
activ
antibodi
gener
rm
week
evalu
prnt
assay
vaccin
monkey
signific
neutralis
activ
antizikv
reciproc
prnt
dilut
titr
rang
averag
standard
error
mean
figur
prnt
titr
directli
correl
elisa
titr
data
shown
abil
immun
sera
vaccin
rm
block
zikv
infect
vero
cell
neuroblastoma
sknsh
neural
progenitor
cell
vitro
examin
ifa
zikv
strain
preincub
sera
dilut
rmimmun
sera
ad
monolay
cell
type
protect
zikv
infect
diseas
ifnar
mice
follow
zikvprm
immunis
exploratori
studi
ifnar
mice
n
challeng
plaqueform
unit
pfu
isol
administ
either
subcutan
sc
intraperiton
ip
intracrani
ic
intraven
iv
rout
challeng
anim
monitor
clinic
sign
infect
includ
routin
measur
bodi
weight
well
inspect
sign
moribund
condit
hind
limb
weak
paralysi
chang
gener
appear
mice
observ
first
day
inocul
howev
fourth
day
mice
group
demonstr
reduc
overal
activ
decreas
mobil
hunch
postur
often
accompani
hindlimb
weak
decreas
water
intak
obviou
weight
loss
anim
succumb
infect
day
day
regardless
rout
viral
challeng
supplementari
figur
e
basi
data
subsequ
studi
evalu
zikvprmemedi
protect
model
use
sc
rout
challeng
protect
efficaci
zikvprm
vaccin
next
evalu
ifnar
mous
model
two
group
mice
n
immunis
vaccin
im
rout
electroporationmedi
deliveri
zikvprm
vaccin
also
two
group
mice
immunis
im
rout
electroporationmedi
deliveri
control
vector
immunis
perform
two
time
two
week
apart
anim
challeng
day
week
post
second
immunis
one
set
control
vaccin
mice
receiv
pfu
sc
rout
set
group
challeng
total
pfu
sc
rout
week
post
challeng
zikvprm
vaccin
anim
surviv
wherea
singleor
doubledos
challeng
control
surviv
figur
b
challeng
vaccin
anim
without
sign
diseas
includ
induct
zikv
specif
cellular
immun
respons
follow
zikvprm
vaccin
nonhuman
primat
nhp
elispot
analysi
measur
secret
peripher
blood
mononuclear
cell
pbmc
respons
zikvprm
immunis
rhesu
macaqu
immunis
intraderm
mg
zikvprm
plasmid
week
administ
mg
two
site
immunis
immedi
follow
intraderm
electropor
pbmc
isol
preimmunis
week
use
elispot
assay
detect
cell
respons
stimul
zikvprm
peptid
describ
materi
method
section
number
produc
cell
obtain
per
million
pbmc
six
peptid
pool
encompass
entir
prme
protein
shown
valu
repres
mean
respons
group
n
sem
b
detect
zikvprmespecif
antibodi
respons
follow
dna
vaccin
antizikv
igg
antibodi
measur
preimmunis
week
elisa
c
endpoint
elisa
titr
anti
zikvenv
antibodi
shown
follow
first
second
immunis
western
blot
analysi
use
week
rm
immun
sera
demonstr
bind
recombin
env
protein
e
prnt
activ
serum
rm
immunis
zikvprm
preimmunis
week
immun
sera
individu
monkey
test
plaquereduct
neutralis
prnt
assay
abil
neutralis
zikv
infect
vitro
prnt
defin
serum
dilut
factor
could
inhibit
input
viru
calcul
prnt
valu
list
monkey
ifn
interferon
zikvprm
precursor
membran
env
zikv
evid
weight
loss
figur
infect
control
mice
viru
produc
mark
decreas
bodi
weight
along
decreas
mobil
hunch
postur
hindlimb
knuckl
walk
andor
paralysi
one
hind
limb
figur
f
potenti
abil
singl
immunis
zikvprm
dna
vaccin
protect
ifnar
mice
zikv
challeng
evalu
group
mice
immunis
im
electropor
either
control
plasmid
zikvprm
vaccin
challeng
week
later
total
dose
pfu
three
week
post
challeng
zikvprm
vaccin
anim
surviv
wherea
control
anim
surviv
figur
determin
gross
histopatholog
chang
brain
tissu
section
sagitt
section
stain
nuclear
structur
counterstain
cytoplasm
structur
use
eosin
figur
mice
kill
day
post
challeng
analysi
histolog
viral
load
zikv
infect
caus
sever
brain
patholog
mice
unvaccin
control
mice
brain
section
show
nuclear
fragment
within
neutrophil
figur
perivascular
cuf
vessel
within
cortex
lymphocyt
infiltr
degener
cell
cerebr
cortex
figur
ii
iii
degener
neuron
within
hippocampu
figur
contrast
zikvprm
vaccin
anim
present
normal
histopatholog
brain
tissu
figur
vi
support
protect
respons
induc
immunis
synthet
zikaprm
vaccin
could
limit
viralinduc
diseas
brain
observ
demonstr
potenti
vaccin
protect
brain
model
consist
amelior
bodi
weight
loss
mobil
impair
vaccin
mice
follow
zikv
challeng
significantli
lower
viral
load
note
blood
figur
brain
figur
zikvprm
vaccin
anim
compar
viral
challeng
vaccin
anim
high
pfu
dose
challeng
group
taken
togeth
data
illustr
zikvprm
dna
vaccinemedi
immun
respons
protect
mice
zikv
challeng
passiv
transfer
antizikv
immun
sera
protect
mice
zikv
infect
next
test
whether
transfer
immun
sera
zikvprm
vaccin
rm
could
prevent
zikvmedi
pathogenesi
ifnar
mice
end
equival
igg
prnt
week
rm
adopt
transfer
ifnar
mice
day
zikv
viral
challeng
two
group
control
mice
includ
one
group
receiv
preimmun
sera
rm
group
receiv
phosphatebuff
salin
figur
singl
immunis
zikvprm
vaccin
provid
protect
zikv
challeng
mice
lack
type
interferon
receptor
mice
immunis
challeng
plaqueform
unit
two
week
post
immunis
surviv
curv
depict
mice
per
group
per
experi
zikvprm
vaccin
prevent
zikvinduc
neurolog
abnorm
mous
brain
b
brain
section
zikvprm
vaccin
group
collect
day
challeng
stain
h
e
haematoxylin
eosin
histolog
section
taken
repres
unprotect
control
anim
show
patholog
nuclear
fragment
within
neuropil
cerebr
cortex
inset
show
higher
magnif
arrow
highlight
nuclear
fragment
ii
perivascular
cuf
vessel
within
cortex
lymphocyt
infiltr
degener
cell
iii
perivascular
cuf
cellular
degener
nuclear
fragment
within
cerebr
cortex
iv
degener
neuron
within
hippocampu
arrow
exampl
normal
tissu
zikvprm
vaccin
mice
appear
within
normal
limit
v
vi
pb
mice
receiv
pb
control
sera
lost
origin
bodi
weight
cours
infect
die
day
post
infect
vaccin
immun
sera
rm
transfer
infectionsuscept
mice
anim
lost
weight
day
subsequ
regain
begin
day
ultim
surviv
infecti
challeng
figur
demonstr
abil
nhp
sera
transfer
confer
protect
clinic
manifest
zikv
infect
follow
viral
challeng
figur
repeat
experi
perform
evalu
efficaci
immun
serum
transfer
protect
challeng
zikv
surviv
among
zikvprm
immun
sera
recipi
rang
studi
show
antizikv
vaccin
immun
sera
abil
confer
signific
protect
zikv
infect
absenc
acquir
adapt
antizikv
immun
respons
seriou
concern
rais
recent
spread
zikv
associ
pathogenesi
human
current
licens
vaccin
therapeut
emerg
infecti
agent
recent
collect
experiment
zikv
vaccin
shown
lower
viral
load
post
challeng
nonpathogen
anim
infect
model
data
encourag
regard
import
examin
addit
novel
vaccin
approach
target
zika
addit
model
similar
suscept
human
might
show
diseas
evalu
synthet
dna
vaccin
design
express
novel
consensu
zikvprm
e
antigen
immunogen
follow
electroporationenhanc
immunis
mice
nonhuman
primat
observ
zikvprm
dna
vaccin
immunogen
gener
antigenspecif
cell
bind
neutralis
antibodi
mice
nhp
uniqu
nhp
immunis
zikvprm
electropor
intraderm
rout
use
lower
voltag
smaller
transfect
area
im
electropor
recent
describ
studi
approach
may
provid
advantag
clinic
set
zikvprm
consensu
construct
includ
design
chang
potenti
nxst
motif
remov
put
glycosyl
site
delet
glycosyl
site
correl
improv
bind
type
bnab
broadli
neutralis
antibodi
zikv
protein
antibodi
respons
induc
consensu
zikvprm
appear
robust
case
superior
magnitud
elicit
similarli
develop
zikvprm
brazil
zikvprm
vaccin
construct
sequenc
match
origin
isol
recent
circul
zikv
strain
brazil
respect
support
studi
provid
insight
effect
incorpor
design
chang
induc
immun
respons
pathogen
challeng
model
zikv
compar
put
protect
natur
immun
respons
zikvprm
vaccin
ifnar
mice
strain
mice
respond
robust
humor
immun
respons
immunis
zikvprm
tcell
respons
also
induc
appear
robust
wildtyp
compar
induc
ifnar
anim
support
partial
defect
innat
adapt
immun
transit
expect
owe
knockout
phenotyp
mous
howev
base
induct
antigen
specif
immun
model
use
evalu
impact
vaccin
infect
pathogenesi
singl
vaccin
zikvprm
ifnar
mice
protect
diseas
death
model
includ
protect
neuropathogenesi
flavivirusneutralis
antibodi
direct
env
antigen
thought
key
role
protect
diseas
idea
support
directli
passiv
antibodi
transfer
experi
anim
model
indirectli
epidemiolog
data
prospect
studi
geograph
area
prone
mosquitoborn
viral
infect
although
immunis
ifnar
mice
zikvprm
dna
vaccin
well
serum
transfer
immunis
nhp
protect
murin
model
ifnar
vaccin
oppos
serumtransf
mice
exhibit
greater
control
weight
loss
indic
control
pathogenesi
although
addit
studi
need
result
potenti
suggest
role
tcell
respons
aspect
protect
model
addit
observ
control
ifnar
mice
recov
challeng
remain
viral
posit
pcr
least
sever
week
suggest
addit
benefit
vaccin
limit
potenti
sexual
vector
born
transmiss
studi
extend
prior
find
support
potenti
vaccin
case
synthet
dna
vaccin
impact
prevent
diseas
suscept
host
maintain
dmem
dulbecco
modifi
eagl
medium
gibcoinvitrogen
carlsbad
ca
usa
supplement
fetal
bovin
serum
fb
penicillin
streptomycin
passag
upon
confluenc
zikv
viru
strain
kind
gift
dr
susan
weiss
bioqual
md
amplifi
vero
cell
stock
titr
standard
plaqu
assay
vero
cell
fiveto
sixweekold
femal
jackson
laboratori
bar
harbor
usa
ifnar
mmrrc
repositoryth
jackson
laboratori
mice
hous
treat
vaccin
temperaturecontrol
lightcycl
facil
accord
nation
institut
health
wistar
public
health
agenc
canada
iacuc
institut
anim
care
use
committe
guidelin
rm
hous
treatedvaccin
bioqual
md
usa
studi
carri
strict
accord
recommend
describ
guid
care
use
laboratori
anim
nih
offic
anim
welfar
us
depart
agricultur
anim
immunis
work
approv
bioqual
anim
care
use
committe
iacuc
bioqual
accredit
american
associ
accredit
laboratori
anim
care
procedur
carri
ketamin
anaesthesia
train
personnel
supervis
veterinari
staff
effort
made
protect
welfar
anim
minimis
anim
suffer
accord
weatheral
report
use
nonhuman
primat
recommend
anim
hous
adjoin
individu
primat
cage
allow
social
interact
control
condit
humid
temperatur
light
h
h
dark
cycl
food
water
avail
ad
libitum
anim
monitor
twice
daili
fed
commerci
monkey
chow
treat
fruit
twice
daili
train
personnel
zikvprm
plasmid
dna
construct
encod
fulllength
precursor
membran
prm
plu
env
e
construct
encod
consensu
capsid
protein
synthesis
consensu
strategi
use
consensu
sequenc
determin
align
current
zikv
prme
protein
sequenc
vaccin
insert
genet
optimis
ie
codon
rna
optimis
enhanc
express
human
ige
leader
sequenc
ad
facilit
express
construct
synthesis
commerci
genscript
nj
usa
subclon
modifi
express
vector
control
cytomegaloviru
immediateearli
promot
describ
final
construct
name
zikvprm
vaccin
control
plasmid
backbon
addit
number
match
dna
construct
encod
prm
e
gene
brazilian
outbreak
strain
also
design
evalu
largescal
amplif
dna
construct
carri
inovio
pharmaceut
inc
plymouth
meet
pa
usa
purifi
plasmid
dna
formul
water
immunis
size
dna
insert
confirm
via
agaros
gel
electrophoresi
phylogenet
analysi
perform
multipl
align
clustalw
use
mega
version
softwar
dna
immunis
electroporationmedi
deliveri
enhanc
femal
mice
week
old
ifnar
mice
week
old
immunis
dna
total
volum
water
deliv
tibiali
anterior
muscl
vivo
electropor
deliveri
vivo
electropor
deliv
cellectra
adapt
constant
current
electropor
devic
inovio
pharmaceut
site
immedi
follow
dna
inject
threeprong
cellectra
minim
invas
devic
mm
muscl
squarewav
puls
deliv
triangular
threeelectrod
array
consist
solid
stainless
steel
electrod
two
constant
current
puls
amp
deliv
msecpuls
separ
delay
protocol
use
electropor
previous
describ
detail
mice
immunis
three
time
interv
kill
week
final
immunis
blood
splenocyt
collect
immunis
analysi
cellular
humor
immun
respons
rhesu
macaqu
immunogen
studi
five
rhesu
macaqu
immunis
intraderm
two
site
two
time
interv
mg
zikvprm
vaccin
electropor
deliv
amp
immedi
use
devic
describ
mous
immunis
vitro
express
studi
transfect
perform
use
genejamm
reagent
follow
manufactur
protocol
agil
santa
clara
ca
usa
briefli
cell
grown
confluenc
mm
dish
transfect
zikvprm
vaccin
cell
collect
day
transfect
wash
twice
pb
lyse
cell
lysi
buffer
cell
signal
technolog
danver
usa
western
blot
use
verifi
express
zikvprm
protein
harvest
cell
lysat
immun
specif
mous
rm
serum
use
either
panflaviviru
antibodi
immun
sera
zikvprm
vaccin
mice
describ
previous
brief
bistri
nupag
gel
life
technolog
carlsbad
ca
usa
load
zikv
env
recombin
protein
rzikv
transfect
cell
lysat
supernat
odyssey
protein
molecular
weight
marker
product
gel
run
v
min
mop
buffer
protein
transfer
onto
nitrocellulos
membran
use
iblot
gel
transfer
devic
life
technolog
membran
block
pb
odyssey
block
buffer
licor
bioscienc
lincoln
ne
usa
h
room
temperatur
detect
vaccin
express
antiflaviviru
group
antigen
antibodi
dilut
immun
serum
mice
rm
dilut
odyssey
block
buffer
tween
biorad
hercul
ca
usa
incub
membran
overnight
membran
wash
pbst
incub
appropri
secondari
antibodi
goat
antimous
licor
bioscienc
mous
serum
flaviviru
antibodi
goat
antihuman
licor
bioscienc
rm
sera
dilut
mous
sera
h
room
temperatur
wash
membran
imag
odyssey
infrar
imag
licor
bioscienc
immunofluoresc
assay
cell
grown
coverslip
transfect
zikvprm
vaccin
two
day
transfect
cell
fix
paraformaldehyd
min
nonspecif
bind
block
normal
goat
serum
dilut
pb
room
temperatur
h
slide
wash
pb
min
subsequ
incub
sera
immunis
mice
rm
dilut
overnight
slide
wash
describ
incub
appropri
secondari
antibodi
goat
antimous
mous
serum
goat
antihuman
rm
serum
sigma
st
loui
mo
usa
dilut
room
temperatur
h
wash
flouroshield
mount
media
dapi
abcam
cambridg
usa
ad
stain
nuclei
cell
coverslip
mount
slide
observ
microscop
evo
cell
imag
system
life
technolog
addit
vero
sknsh
cell
grown
fourchamb
tissu
cultur
treat
glass
slide
infect
moi
preincub
withwithout
rm
immun
sera
stain
day
post
zikv
infect
use
panflaviviru
antibodi
describ
histopatholog
analysi
histopatholog
formalinfix
paraffinembed
brain
tissu
section
thick
sagitt
section
place
superfrost
microscop
slide
fisher
scientif
hampton
nh
usa
back
overnight
section
deparaffinis
use
two
chang
xylen
rehydr
immers
ethanol
section
stain
nuclear
structur
use
harri
haematoxylin
surgipath
buffalo
grove
il
usa
min
follow
differenti
acid
alcohol
surgipath
treatment
scott
tap
water
min
subsequ
section
counterstain
cytoplasm
structur
use
eosin
surgipath
min
slide
dehydr
ethanol
clear
xylen
mount
use
permount
fisher
scientif
singlecel
suspens
splenocyt
prepar
mice
briefli
spleen
mice
collect
individu
ml
rpmi
supplement
fb
process
stomach
paddl
blender
aj
seward
co
ltd
high
speed
process
spleen
sampl
filter
mm
nylon
filter
centrifug
min
cell
pellet
resuspend
ml
ack
ammoniumchloridepotassium
lysi
buffer
zika
viru
prm
envelopebas
dna
vaccin
k
muthumani
et
al
life
technolog
min
room
temperatur
pb
ad
stop
reaction
sampl
centrifug
min
cell
pellet
resuspend
pass
mm
nylon
filter
use
elispot
assay
flow
cytometr
analysi
rm
blood
ml
time
point
collect
edta
tube
pbmc
isol
use
standard
ficollhypaqu
procedur
accuspin
tube
sigmaaldrich
st
loui
mo
usa
five
millilitr
blood
also
collect
sera
tube
time
point
sera
isol
flow
cytometri
intracellular
cytokin
stain
assay
splenocyt
ad
plate
well
stimul
zikvprm
pool
peptid
h
co
presenc
protein
transport
inhibitor
cocktail
brefeldin
monensin
ebiosci
san
diego
ca
usa
cell
stimul
cocktail
plu
protein
transport
inhibitor
pma
phorbol
ionomycin
brefeldin
monensin
ebiosci
use
posit
control
media
neg
control
cell
stain
surfac
intracellular
protein
describ
manufactur
instruct
bd
bioscienc
san
diego
ca
usa
briefli
cell
wash
fac
buffer
pb
contain
sodium
azid
fb
surfac
stain
flourochromeconjug
antibodi
cell
wash
fac
buffer
fix
permeabilis
use
bd
cytofixctyoperm
tm
bd
bioscienc
accord
manufactur
protocol
follow
intracellular
stain
follow
antibodi
use
surfac
stain
livedead
fixabl
violet
dead
cell
stain
kit
invitrogen
clone
bd
bioscienc
fitc
clone
ebiosci
clone
bd
bioscienc
clone
biolegend
san
diego
ca
usa
intracellular
stain
follow
antibodi
use
apc
clone
biolegend
pe
clone
ebiosci
san
diego
ca
usa
percp
clone
biolegend
clone
ebiosci
data
collect
use
lsrii
flow
cytomet
bd
bioscienc
analys
use
flowjo
softwar
tree
star
ashland
usa
briefli
elispot
plate
millipor
billerica
usa
coat
antimous
captur
ab
r
system
minneapoli
mn
usa
incub
overnight
follow
day
plate
wash
pb
block
h
bsa
two
hundr
thousand
splenocyt
immunis
mice
ad
well
incub
overnight
co
presenc
media
alon
neg
control
media
pmaionomycin
posit
control
media
peptid
pool
consist
overlap
nine
amino
acid
span
length
zikv
prme
protein
genscript
piscataway
nj
usa
h
cell
wash
incub
overnight
biotinyl
antimous
ab
r
system
minneapoli
mn
usa
streptavidinalkalin
phosphatas
r
system
ad
well
wash
incub
h
room
temperatur
plate
wash
ptoluidin
salt
nitro
blue
tetrazolium
chlorid
chromogen
colour
reagent
r
system
ad
last
plate
rins
distil
water
dri
room
temperatur
sfu
quantifi
autom
elispot
reader
ctl
limit
shaker
height
oh
usa
raw
valu
normalis
sfu
per
million
splenocyt
rm
sampl
elispot
pro
monkey
kit
mabtech
cincinnati
oh
usa
use
describ
manufactur
two
hundr
thousand
pbmc
stimul
peptid
pool
plate
wash
spot
develop
count
describ
humor
immun
respons
antibodybind
elisa
elisa
use
determin
titr
mous
rm
sera
previous
describ
briefli
purifi
rzikv
protein
use
coat
microtit
plate
nalgen
nunc
intern
napervil
il
usa
overnight
block
fb
pb
least
hour
plate
wash
four
time
pbst
pb
serum
sampl
immunis
mice
rm
serial
dilut
fb
ad
plate
incub
h
room
temperatur
plate
wash
four
time
pbst
incub
hrpconjug
antimous
igg
sigma
dilut
mous
sera
h
room
temperatur
rm
sera
antimonkey
igg
hrp
southern
biotech
birmingham
al
usa
use
dilut
h
room
temperatur
bound
enzym
detect
ad
sigmafast
opd
ophenylenediamin
dihydrochlorid
substrat
solut
accord
manufactur
instruct
sigmaaldrich
st
loui
mo
usa
reaction
stop
min
addit
n
h
optic
densiti
nm
read
synergi
plate
reader
mous
rm
serum
sampl
assay
duplic
endpoint
titr
determin
use
method
describ
frey
et
al
neutralis
prnt
assay
prnt
involv
vero
cell
describ
previous
briefli
heatinactiv
mous
rm
sera
serial
dilut
serumfre
dmem
incub
equal
volum
zikv
pfu
h
mixtur
ad
confluent
layer
vero
cell
left
adsorpt
h
dmem
media
softagar
overlay
ad
cell
plate
incub
day
agar
overlay
remov
cell
fix
paraformaldehyd
wash
pb
stain
crystal
violet
solut
wash
pb
plate
left
dri
plaqu
assay
done
plate
scan
autom
immunospot
reader
ctl
limit
plaqu
sampl
well
neg
control
dmem
posit
control
pfu
zikv
viru
well
count
use
autom
softwar
provid
elispot
reader
percentag
plaqu
reduct
calcul
follow
reduct
averag
number
plaqu
dilutionaverag
number
plaqu
posit
control
well
graphpad
prism
softwar
use
perform
nonlinear
regress
analysi
plaqu
reduct
versu
log
transform
individu
serum
dilut
facilit
linear
interpol
actual
prnt
titr
peak
post
vaccin
respons
median
interquartil
rang
neutralis
calcul
neutralis
target
overal
vaccin
treatment
group
geometr
mean
titr
also
calcul
titr
repres
reciproc
highest
dilut
result
reduct
number
plaqu
zikv
challeng
studi
ifnar
mice
zika
challeng
studi
ifnar
mice
n
immunis
twice
zikaprm
vaccin
mice
challeng
either
pfu
pfu
viru
day
singl
immunis
group
day
one
week
second
immunis
two
immunis
group
post
challeng
anim
weigh
bodi
temperatur
measur
daili
subcutan
locat
temperatur
chip
addit
observ
clinic
sign
diseas
twice
daili
decreas
mobil
hunch
postur
hindlimb
knuckl
walk
partial
paralysi
paralysi
one
hind
limb
hind
limb
blood
drawn
viral
load
determin
criteria
kill
welfar
ground
consist
weight
loss
paralysi
one
hind
limb
brain
treat
mice
immers
rnalat
ambion
waltham
usa
week
store
brain
tissu
weigh
homogenis
rlt
buffer
ml
cryovial
use
tissuelys
qiagen
valencia
ca
usa
stainless
steel
bead
min
cycless
viral
rna
also
isol
blood
rneasi
plu
mini
kit
qiagen
zikv
specif
realtim
rtpcr
assay
utilis
detect
viral
rna
subject
anim
rna
revers
transcrib
amplifi
use
primer
zikv
zikv
probe
zikv
taqman
fast
viru
master
mix
appli
biosystem
foster
citi
ca
usa
standard
curv
gener
parallel
plate
use
quantif
viral
genom
copi
number
steponeplu
realtim
pcr
system
life
technolog
corpor
carlsbad
ca
usa
softwar
version
use
calcul
cycl
threshold
ct
valu
ct
valu
least
one
replic
consid
posit
previous
describ
preble
neg
assay
differ
fold
increas
antibodi
titr
compar
use
mannwhitney
analysi
statist
analysi
perform
use
graphpad
prism
zika
viru
prm
envelopebas
dna
vaccin
k
muthumani
et
al
graphpad
softwar
inc
san
diego
ca
usa
analys
consid
signific
log
transform
appli
end
point
bind
elisa
titr
wholeviru
prnt
titr
